Low-dose methylprednisolone treatment in critically ill patients with severe community-acquired pneumonia

Keyphrases

• Critically Ill Patients 100%
• Severe Community-acquired Pneumonia 100%
• Methylprednisolone Pulse Therapy 100%
• No Significant Difference 66%
• 60-day Mortality 66%
• Placebo 33%
• Non-associated 33%
• Clinical Outcomes 33%
• Treatment Course 33%
• Adjusted Odds Ratio 33%
• Methylprednisolone 33%
• Randomized Placebo-controlled Trial 33%
• Adult Patients 33%
• Bolus 33%
• Long-term Mortality 33%
• Pneumonia 33%
• Intensive Care Unit Admission 33%
• All-cause Mortality 33%
• Days of Treatment 33%
• Mechanical Ventilation 33%
• Long-term Morbidity 33%
• Veterans Affairs Medical Center 33%
• Pulmonary Inflammation 33%
• Hospital Presentations 33%
• Systemic Inflammation 33%

Medicine and Dentistry

• Methylprednisolone 100%
• Community-Acquired Pneumonia 100%
• Low Drug Dose 100%
• Placebo 50%
• Odds Ratio 25%
• Downregulation 25%
• Controlled Clinical Trial 25%
• Artificial Respiration 25%
• Intensive Care Unit 25%
• Arm 25%
• Veterans Affairs 25%
• Pneumonia 25%
• All Cause Mortality 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Community Acquired Pneumonia 100%
• Methylprednisolone 100%
• Placebo 50%
• Controlled Clinical Trial 25%
• All Cause Mortality 25%
• Pneumonia 25%